Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1295 clinical trials
Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.

metastasis
  • 734 views
  • 16 Oct, 2022
  • 181 locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

  • 0 views
  • 07 Oct, 2022
  • 170 locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

  • 398 views
  • 07 Oct, 2022
  • 170 locations
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures …

rare diseases
other disease
  • 4 views
  • 15 Jul, 2022
  • 2 locations
A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira to One of Its Biosimilar

Biosimilars represent great potential in cost saving and reinvestment opportunities in healthcare. Biosimilars of adalimumab appear to be clinically equivalent to the reference product in patients with rheumatoid arthritis and psoriasis. No data are currently available in IBD patients. Real-life data are needed. Minimizing the switch back is another clinical …

  • 0 views
  • 25 Jan, 2021
  • 1 location
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis (Tys at Home)

administration are also evaluated as secondary objectives as well as medico-economic assessment of the method. Data will be collected for a 12-month retrospective period and a 12-month prospective period

tysabri
MRI
natalizumab
  • 0 views
  • 06 Apr, 2022
  • 18 locations
Using Smartphone Sensor Technology to Characterize Ambulatory Patterns of Participants With Peripheral Artery Disease

The investigators plan to use smartphone and wearable sensor technology to characterize the activity patterns of participants with peripheral artery disease (PAD) (n=24) participating in a 12

  • 0 views
  • 14 Mar, 2022
  • 1 location
Assessing Adolescent Use of Nexplanon Over Time

The purpose of this study is to compare Nexplanon decision-making, uptake, satisfaction and contraceptive outcomes (continuation, switching, discontinuation) over a 12-month period among

nexplanon
Accepts healthy volunteers
contraceptive use
  • 0 views
  • 17 Jun, 2022
  • 1 location
Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders (PTSD)

-based questionnaires online. In Aim 2 of this study will monitor the effectiveness of a 12 week therapy program on bowel symptoms and overall quality of life.

constipation
anorectal manometry
bowel dysfunction
balloon expulsion test
  • 58 views
  • 25 Mar, 2022
  • 1 location
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) (DOPER)

Descriptive : A 12-months multicenter, observational, prospective cohort study. Population : IBD patients under stable clinical and biological remission will be proposed to switch from the IV

mercaptopurine
azathioprine
vedolizumab
remission
methotrexate
  • 0 views
  • 04 Oct, 2022
  • 1 location